bluebird bio (BLUE) Provides Updated Findings from Reported Case of AML in LentiGlobin for Sickle Cell Disease Gene Therapy Program

Go back to bluebird bio (BLUE) Provides Updated Findings from Reported Case of AML in LentiGlobin for Sickle Cell Disease Gene Therapy Program
BLUEBIRD BIO (NASDAQ: BLUE) Delayed: 30.10 +0.60 (2.03%)
Previous Close $29.50    52 Week High $95.28 
Open $29.40    52 Week Low $35.37 
Day High $30.15    P/E N/A 
Day Low $29.21    EPS $-1.81 
Volume 213,545